Reversal of tumor-induced immunosuppression by TGF-β inhibitors

Investigational New Drugs

Volumn 21, Issue 1, 2003, Pages 21-32

  Wojtowicz Praga, Slawomir ^a  

^a NONE   (United States)

Author keywords

Cancer; Immunosuppression; Malignancy; TGF ; TGF inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; AP 12009; HUMANIZED MONOCLONAL ANTIBODY CAT 152; HUMANIZED MONOCLONAL ANTIBODY CAT 192; IMMUNOSUPPRESSIVE AGENT; LERDELIMUMAB; MURINE MONOCLONAL ANTIBODY 1D11; MURINE MONOCLONAL ANTIBODY 2G7; PROTEIN INHIBITOR; SMAD PROTEIN; SMAD PROTEIN INHIBITOR; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; CLINICAL TRIAL; CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; GENE THERAPY; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; DNA-BINDING PROTEINS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY, ACTIVE; NEOPLASM METASTASIS; NEOPLASMS; SMAD PROTEINS; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0038353468     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022951824806     Document Type: Review

References (132)

1. Rifkin DB, Kojima S, Abe M, Harpel JG: TGF-beta: structure, function, and formation. Thromb Haemost 70: 177-179, 1993
2. Kingsley DM: The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 8: 133-146, 1994
3. Okragly A, Balwit JM, Haak-Frendscho: Transforming growth factor beta-1 (TGF-beta-1): a biological paradox. Promega Notes Mag 10: 10-18, 1994
4. Norgaard P, Hougaard S, Poulsen HS, Spang-Thomsen M: Transforming growth factor β and cancer. Cancer Treat Rev 21: 367-403, 1995
5. Kim SJ, Romeo D, Yoo YD, Park K: Transforming growth factor-beta: expression in normal and pathological conditions. Horm Res 42: 5-8, 1994
6. Miyazono K, Ichijo H, Heldin CH: Transforming growth factor-beta: latent forms, binding proteins and receptors. Growth Factors 8: 11-22, 1993
7. Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF: Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol 131: 539-549, 1995
8. Locci P, Marinucci L, Lilli C, Martinese D, Becchetti E: Transforming growth factor beta 1-hyaluronic acid interaction. Cell Tissue Res 281: 317-324, 1995
9. Flaumenhaft R, Kojima S, Abe M, Rifkin DB: Activation of latent transforming growth factor beta. Adv Pharmacol 24: 51-76, 1993
10. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE: Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem 269: 26775-26782, 1994
11. Horimoto M, Kato J, Takimoto R, Terui T, Mogi Y, Niitsu Y: Identification of a transforming growth factor beta-1 activator derived from a human gastric cancer cell line. Br J Cancer 72: 676-682, 1995
12. Sasaki A, Naganuma H, Satoh E, Nagasaka M, Isoe S, Nakano S, Nukui H: Secretion of transforming growth factor-beta 1 and -beta 2 by malignant glioma cells. Neurol Med Chir 35: 423-430, 1995
13. Yu Q, Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 14: 163-176, 2000
14. Wojtowicz-Praga S: Matrix metalloproteinase inhibitors. In: Abelloff MD et al. (eds) Clinical Oncology, 2nd edn, 2000, pp 251-259
15. Lin HY, Moustakas A: TGF-beta receptors: structure and function. Cell Mol Biol 40: 337-349, 1994
16. Okadome T, Yamashita H, Franzen P, Moren A, Heldin CH, Miyazono K: Distinct roles of the intracellular domains of transforming growth factor-beta type I and type II receptors in signal transduction. J Biol Chem 269: 30753-30756, 1994
17. Wrana JL: TGF-β receptors and signaling mechanisms. Miner Electrolyte Metab 24: 120-130, 1998
18. Lu KX, Lodish HF: Signaling by chimeric erythropoietin-TGF-β receptors: homodimerization of the cytoplasmic domain of type I TGF-β receptor and heterodimerization with type II receptor are both required for intracellular signal transduction. EMBO J 15: 4485-4496, 1996
19. Hartsough MT, Mulder KM: Transforming growth factor-β signaling in epithelial cells. Pharmacol Ther 75: 21-41, 1997
20. Hartsough MT, Frey RS, Zipfel PA, Buard A, Cook SJ, McCormick F, Mulder KM: Altered transforming growth factor-β signaling in epithelial cells when Ras activation is blocked. J Biol Chem 271: 22368-22375, 1996
21. Frey RS, Mulder KM: Involvement of extracellular signal-regulated and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor β in the negative growth control of breast cancer cells. Cancer Res 57: 628-633, 1997
22. Heldin CH, Miyazono K, ten Dijke P: TGF-β signaling from cell membrane to nucleus through SMAD proteins. Nature (Lond.) 390: 465-471, 1997
23. Kretzschmar M, Massague J: SMADs: mediators and regulators of TGF-β signaling. Curr Opin Genet Dev 8: 103-111, 1998
24. Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, ten Dijke P: TGF-β receptor-mediated signaling through Smad2, Smad3 and Smad 4. EMBO J 16: 5353-5362, 1997
25. Liu X, Yue J, Frey RS, Zhu Q, Mulder KM: Transforming growth factor β signaling through Smad1 in human breast cancer cells. Cancer Res 58: 4752-4757, 1998
26. Padgett RW, Cho SH, Evangelista C: Smads are the central component in transforming growth factor-β signaling. Pharmacol Ther 78: 47-52, 1998
27. Zhang Y, Musci T, Derynck R: The tumor suppressor Smad4/DPC4 as a central mediator of Smad function. Curr Biol 7: 270-276, 1996
28. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K: Smad6 inhibits signaling by the TGF-β superfamily. Nature (Lond.) 389: 622-626, 1997
29. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P: Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signaling. Nature (Lond.) 389: 631-635, 1997
30. Zhang YE, Yu L, Hebert MC: Transforming Growth Factor-B receptor activated p38 MAP kinase mediates Smad-independent TGF-B responses. PAACR: 762, 2002 (Abstract)
31. Wojtowicz-Praga S: Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 20: 165-177, 1997
32. Reiss M, Barcellos-Hoff MH: Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat 45: 81-95, 1997
33. Baillie R, Coombes RC, Smith J: Multiple forms of TGF-beta 1 in breast tissues: a biologically active form of the small latent complex of TGF-beta 1. Eur J Cancer 32A: 1566-1573, 1996
34. Steiner MS, Zhou ZZ, Tonb DC, Barrack ER: Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology 135: 2240-2247, 1994
35. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC: Association of transforming growth factor-beta 1 with prostate cancer: an immunohisto-chemical study. Hum Pathol 24: 4-9, 1993
36. Fischer JR, Darjes H, Lahm H, Schindel M, Drings P, Krammer PH: Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines. Eur J Cancer 30A: 2125-2129, 1994
37. Damstrup L, Rygaard K, Spang-Thomsen M, Skovgaard Poulsen H: Expression of transforming growth factor beta (TGF-beta) receptors and expression of TGF-beta 1, TGF-beta 2 and TGF-beta 3 in human small cell lung cancer cell lines. Br J Cancer 67: 1015-1021, 1993
38. Takanami I, Imamura T, Hashizume T, Kikuchi K, Yamamoto Y, Kodaira S: Transforming growth factor beta 1 as a prognostic factor in pulmonary adenocarcinoma. J Clin Pathol 47: 1098-1100, 1994
39. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A: High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 4: 549-554, 1995
40. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, Korc M: Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105: 1846-1856, 1993
41. Bristow RE, Baldwin RL, Yamada SD, Korc M, Karlan BY: Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma. Cancer 85: 658-668, 1999
42. Miyamoto H, Kubota Y, Shuin T, Torigoe S, Dobashi Y, Hosaka M: Expression of transforming growth factor-beta 1 in human bladder cancer. Cancer 75: 2565-2570, 1995
43. Williams AO, Ward JM, Li JF, Jackson MA, Flanders KC: Immunohistochemical localization of transforming growth factor-beta 1 in Kaposi's sarcoma. Hum Pathol 26: 469-473, 1995
44. Reed JA, McNutt NS, Prieto VG, Albino AP: Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol 145: 97-104, 1994
45. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT: Anti-transforming growth factor beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen Natural Killer cell activity. J Clin Invest 92: 2569-2576, 1993
46. Wojtowicz-Praga S, Verma UN, Wakefield L, Esteban JM, Hartmann D, Mazumder A: Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J Immunother 19: 169-175, 1996
47. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 93: 2909-2914, 1996
48. Wright JA, Turley E, Greenberg AH: Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy. Crit Rev Oncog 4: 473-492, 1993
49. Assoian RK, Sporn MB: Type β transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol 102: 1217-1223, 1996
50. Puolakkainen P, Twardzik D, Ranchalis J, Moroni M, Mandeli J, Paciucci PA: Increase of plasma transforming growth factor beta (TGF-beta) during immunotherapy with IL-2. Cancer Invest 13: 583-589, 1995
51. Wojtowicz-Praga S: Transforming growth factor-β and tumor-induced immunosuppression. Electr J Oncol (http://ejo.univ-lyon1.fr), 1: 52-63, 2000
52. Derynck R, Akhurst RJ, Balmain A: TGF-β signaling in tumor suppression and cancer progression. Nat Genet 29(2): 117-129, 2001
53. Pasche B: Role of transforming growth factor beta in cancer. J Cell Physiol 186: 153-168, 2001
54. Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, George D: Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci USA 91(13): 6002-6006, 1994
55. Francis-Thickpenny KM, Richardson DM, van Ee CC, Love DR, Winship IM, Baguley BC, Chenevix-Trench G, Shelling AN: Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma. Br J Cancer 85(5): 687-691, 2001
56. Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T, Higashino K: Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta 1137: 189-196, 1992
57. Khew-Goodall Y, Gamble JR, Vadas MA: Regulation of adhesion and adhesion molecules in endothelium by transforming growth factor-beta. Curr Top Microbiol Immunol 184: 187-199, 1993
58. Newman MJ: Transforming growth factor beta and the cell surface in tumor progression. Cancer Metastasis Rev 12: 239-254, 1993
59. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN: Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg 76: 799-804, 1992
60. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC: Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258: 1795-1798, 1992
61. Ebert EC: Inhibitory effects of transforming growth factor-beta (TGF-beta) on ain functions of intraepithelial lymphocytes. Clin Exp Immunol 115: 415-420, 1999
62. Geller RL, Smyth MJ, Strobl SL, Bach FH, Ruscetti FW, Longo DL, Ochoa AC: Generation of lymphokine activated killer activity in T cells. Possible regulatory circuits. J Immunol 146: 3280-3288, 1991
63. Ruscetti F, Varesio L, Ochoa A, Ortaldo J: Pleiotropic effects of transforming growth factor-beta on cells of the immune system. Ann NY Acad Sci 685: 488-500, 1993
64. Naganuma H, Sasaki A, Satoh E, Nagasaka M, Nakano S, Isoe S, Tasaka K, Nukui H: Inhibition of tumor necrosis factor-alpha and -beta secretion by lymphokine activated killer cells by transforming growth factor-beta. Jpn J Cancer Res 85: 952-957, 1994
65. Chao CC, Hu S, Sheng WS, Tsang M, Peterson PK: Tumor necrosis factor-alpha mediates the release of bioactive transforming growth factor-beta in murine microglial cell cultures. Clin Immunol Immunopathol 77: 358-365, 1995
66. Gray JD, Hirokawa M, Horwitz DA: The role of transforming growth factor beta in the generation of suppression: an interaction between CD8+ T and NK cells. J Exp Med 180: 1937-1942, 1994
67. Stavnezer J: Regulation of antibody production and class switching by TGF-beta. J Immunol 155: 1647-1651, 1995
68. Hoefer M, Anderer FA: Anti-(transforming growth factor beta) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice. Cancer Immunol Immunother 41: 302-308, 1995
69. Dziegielewska KM, Brown WM, Casey SJ, Christie DL, Foreman RC, Hill RM, Saunders NR: The complete cDNA and amino acid sequence of bovine fetuin. Its homology with alpha 2HS glycoprotein and relation to other members of the cystatin superfamily. J Biol Chem 265(8): 4354-4357, 1990
70. Triffitt JT, Gebauer I, Ashton BA, Owen ME, Reynolds JJ: Origin of plasma alpha2HS-glycoprotein and its accumulation in bone. Nature 262(5565): 226-227, 1976
71. Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW: Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 271: 12755-12761, 1996
72. Binkert C, Demetriou M. Sukhu B, Szweras M, Tenenbaum HC, Dennis JW: Regulation of osteogenesis by fetuin. J Biol Chem 274(40): 28514-28520, 1999
73. Harthun NL, Weaver AM, Brinckerhoff LH, Deacon DH, Gonias SL, Slingluff CL Jr: Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2. J Immunother 21: 85-94, 1998
74. Yamaguchi Y, Mann DM, Ruoslahti E: Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346(6281): 281-284, 1990
75. Hildebrand A, Romaris M, Rasmussen LM, Heinegard D, Twardzik DR, Border WA, Ruoslahti E: Interaction of the small interstitial proteoglycans biglycan, decorin and fibro-modulin with transforming growth factor beta. Biochem J 302(Pt 2): 527-534, 1994
76. Takeuchi Y, Kodama Y, Matsumoto T: Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity. J Biol Chem 269(51): 32634-32638, 1994
77. Stander M, Naumann U, Dumitrescu L, Heneka M, Loschmann P, Gulbins E, Dichgans J, Weller M: Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther 5: 1187-1194, 1998
78. Lopez-Casillas F, Payne HM, Andres JL, Massague J: Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 124(4): 557-568, 1994
79. Bandyopadhyay A, Lopez-Casillas F, Sun L: Administration of a recombinant TGF-beta type III receptor (soluble RIII) inhibits angiogenesis and tumor growth in human breast cancer xenograft. PAACR: 436, 2002 (Abstract)
80. Won J, Kim H, Park EJ, Hong Y, Kim SJ, Yun Y: Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy. Cancer Res 59: 1273-1277, 1999
81. Dukhanina OI, Yang Y, Tang B, Mamura M, Letterio J, Anver M, Green J, Merlino G, Wakefield L: Expression of a soluble TGF-β antagonist in vivo protects against metastasis without adverse side-effects. PAACR: 3333, 2000 (Abstract).
82. Ge R, Liu D, Joly A, Dugar S, Chakravarty J, Henson M, McEnroe G, Schreiner G, Reiss M: Selective inhibition of transforming growth factor-β signaling blocks invasiveness of human breast carcinoma cells in vitro. PAACR: 4746, 2002 (Abstract)
83. Zhang Y, Musci T, Derynck R: The tumor suppressor Smad4/DPC 4 as a central mediator of Smad function. Curr Biol 7: 270-276, 1997
84. Zhao J, Lee M, Smith S, Warburton D: Abrogation of Smad3 and Smad2 or of Smad4 gene expression positively regulates murine embryonic lung branching morphogenesis in culture. Dev Biol 194: 182-195, 1998
85. Saha D, Datta PK, Beauchamp RD: Oncogenic ras represses transforming growth factor-beta/Smad signaling by degrading tumor suppressor Smad4. J Biol Chem 276(31): 29531-29537, 2001
86. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW, Falb D, Korc M: The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 18(39): 5363-5372, 1999
87. Bottinger EP, Factor VM, Tsang ML, Weatherbee JA, Kopp JB, Qian SW, Wakefield LM, Roberts AB, Thorgeirsson SS, Sporn MB: The recombinant proregion of transforming growth factor β1 (latency-associated peptide) inhibits active transforming growth factor β1 in transgenic mice. Proc Natl Acad Sci USA 93: 5877-5882, 1996
88. Wilkinson KA, Martin TD, Reba SM, Aung H, Redline RW, Boom WH, Toossi Z, Fulton SA: Latency-associated peptide of transforming growth factor beta enhances mycobacteriocidal immunity in the lung during mycobacterium bovis BCG infection in C57BL/6 mice. Infect Immun 68(11): 6505-6508, 2000
89. Gridley DS, Sura SS, Uhm JR, Lin CH, Kettering JD: Effects of anti-transforming growth factor-beta antibody and interleukin-2 in tumor-bearing mice. Cancer Biother (United States) 8: 159-170, 1993
90. Mao XW, Kettering JD, Gridley DS: Immunotherapy with low dose interleukin-2 and anti-transforming growth factorbeta antibody in a murine tumor model. Cancer Biother (United States) 9: 317-327, 1994
91. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397: 530-534, 1999
92. Konneh M: Tranilast, Kissei pharmaceuticals. Idrugs 1(1): 141-146, 1998
93. Ikeda H, Inao M, Fujiwara K: Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells. Biochem Biophys Res Commun 227(2): 322-327, 1996
94. Ward MR, Sasahara T, Agrotis A, Dilley RJ, Jennings GL, Bobik A: Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries. Atherosclerosis 137(2): 267-275, 1998
95. Kondo N, Fukutomi O, Shinbara M, Orii T: Inhibition of interferon-gamma and interleukin-2 production from lymphocytes stimulated with food antigens by an anti-allergic drug. Tranilast, in patients with food-sensitive atopic dermatitis. Biotherapy 8(1): 19-22, 1994
96. Isaji M, Miyata H, Ajisawa Y, Yoshimura N: Inhibition by tranilast of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF)-induced increase in vascular permeability in rats. Life Sci 63(4): 71-74, 1998
97. Isaji M, Miyata H, Ajisawa Y, Takehana Y, Yoshimura N: Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. Br J Pharmacol 122(6): 1061-1066, 1997
98. Platten M, Wild-Bode C, Wick W, Leitlein J, Dichgans J, Weller M: N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells. Int J Cancer 93(1): 53-61, 2001
99. Yashiro M, Chung YS, Sowa M: Tranilast (N-(3,4-dimethoxycirmamoyl) anthranilic acid) down-regulates the growth of scirrhous gastric cancer. Anticancer Res 17(2A): 895-900, 1997
100. Murahashi K, Yashiro M, Inoue T, Nishimura S, Matsuoka T, Sawada T, Sowa M, Hirakawa-Ys Chung K: Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer. Int J Oncol 13(6): 1235-1240, 1998
101. Nie L, Oishi Y, Doi I, Shibata H, Kojima I: Inhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca(2+)-permeable channel. Cell Calcium 22(2): 75-82, 1997
102. Yatsunami J, Aoki S, Fukuno Y, Kikuchi Y, Kawashima M, Hayashi SI: Antiangiogenic and antitumor effects of tranilast on mouse lung carcinoma cells. Int J Oncol 17(6): 1151-1156, 2000
103. Marzo AL, Fitzpatrick DR, Robinson BWS, Scott B: Antisense oligonucleotides specific for transforming growth factor β2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 57: 3200-3207, 1997
104. Fakhrai H, Mantil J, Liu L, Nicholson G, Satter CM, Ruppert J, Krause G, Saadatmandi N, Shawler DL: Treatment of glioma with a TGF-β antisense-modified tumor cell vaccine. PAACR, 714, 2002 (Abstract)
105. Dorigo O, Shawler DL, Royston I, Sobol RE, Berek JS, Fakhrai H: Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model. Gynecol Oncol 71(2): 204-210, 1998
106. Hau P, Zellner A, Bogdahn U, Schulmeyer F, Bele S, Brawanski A, Brysch W, Goldbrunner M, Jachimczak P, Kunst M, Schlingensiepen R, Schlingensiepen K: A phase I/II dose escalation study to evaluate the safety and tolerability of phosphorothioate TGF-beta2 antisense oligonucleotides in patients with malignant glioma. PASCO 37: 2066, 2001 (Abstract)
107. Hau P, Bogdahn U, Schulmeyer F, Brawanski A, Steinbrecher A, Zellner A, Goldbrunner M, Jachimczak P, Kunst M, Stauder G, Schlingensiepen KH, Schlingensiepen R: TGF-beta-2 antisense oligonucleotide AP12009 administered intratumorally to patients with malignant glioma in a clinical phase I/II dose escalation study: safety and preliminary efficacy data. PASCO 38: 109, 2002 (Abstract)
108. Brooks SP, Bernstein ZP, Schneider SL, Gollnick SO, Tomasi B: Role of transforming growth factor-beta1 in the suppressed allostimulatory function of AIDS patients. AIDS 12: 481-487, 1998
109. Shah AH, Lee C: TGF-beta-based immunotherapy for cancer: breaching the tumor firewall. Prostate 45(2): 167-172, 2000
110. Shah AH, Tabayoyong WB, Lee C: Transforming Growth Factor-β signaling in leukocytes is a viable target for retroviral gene therapy in highly aggressive murine melanoma model. PAACR: 2943, 2002 (Abstract)
111. Gorelik L, Flavell RA: Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7(10): 1118-1122, 2001
112. Campbell JD, Cook G, Robertson SE, Fraser A, Boyd KS, Gracie JA, Franklin IM: Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15. J Immunol 167(1): 553-561, 2001
113. Teicher BA, Holden SA, Ara G, Chen G: Transforming growth factor-beta in in vivo resistance. Cancer Chemother Pharmacol 37: 601-609, 1996
114. Nash MA, Loercher AE, Freedman RS: In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin. Cancer Res 59(24): 6192-6196, 1999
115. Rube CE, Uthe D, Schmid KW, Richter KD, Wessel J, Schuck A, Willich N, Rube C: Dose-dependent induction of transforming growth factor beta (TGF-beta) in the lung tissue of fibrosis-prone mice after thoracic irradiation. Int J Radiat Oncol Biol Phys 47(4): 1033-1042, 2000
116. Vujaskovic Z, Groen HJ: TGF-beta, radiation-induced pulmonary injury and lung cancer. Int J Radiat Biol 76(4): 511-516, 2000
117. Anscher MS, Kong FM, Jirtle RL: The relevance of transforming growth factor beta 1 in pulmonary injury after radiation therapy. Lung Cancer 19(2): 109-120, 1998
118. Su-Mi Chung, Jin-Hyoung Kang, Youn-soo Lee, Mi-Ryeong Ryu, Yeon-Shil Kim, Chul-Seung Kay, Sung-Whan Kim, Sei-Chul Yoon: Inhibitory Effect of Tranilast on Radiation-Induced Pneumonitis in C57BL/6 Mouse. PASCO 37, Abstract # 1112, 2001
119. Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, Munley M, Hemdon JE 2nd, Garst J, Crawford J, Jirtle RL: Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. J Clin Oncol 19(17): 3758-3765, 2001
120. Kropf J, Schurek JO, Wollner A, Gressner AM: Immunological measurement of transforming growth factor-beta 1 (TGF-beta 1) in blood; assay development and comparison. Clin Chem 43: 1965-1974, 1997
121. Hazelbag S, Fleuren GJ, Baelde JJ, Schuuring E, Kenter GG, Gorter A: Cytokine profile of cervical cancer cells. Gynecol Oncol 83(2): 235-243, 2001
122. Junker U, Knoefel B, Nuske K, Rebstock K, Steiner T, Wunderlich H, Junker K, Reinhold D: Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine 8(10): 794-798, 1996
123. Kyrtsonis MC, Repa C, Dedoussis GV, Mouzaki A, Simeonidis A, Stamatelou M, Maniatis A: Serum transforming growth factor-beta 1 is related to the degree of immunoparesis in patients with multiple myeloma. Med Oncol 15(2): 124-128, 1998
124. Cook G, Campbell JD, Carr CE, Boyd KS, Franklin IM: Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J Leukoc Biol 66(6): 981-988, 1999
125. Pasini FS, Brentani MM, Kowalski LP, Federico MH: Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa. Head Neck 23(9): 725-732, 2001
126. Matoba H, Sugano S, Yamaguchi N, Miyachi Y: Expression of transforming growth factor-beta1 and transforming growth factor-beta Type-II receptor mRNA in papillary thyroid carcinoma. Horm Metab Res 30(10): 624-628, 1998
127. Yoshida K, Kuniyasu H, Yasui W, Kitadai Y, Toge T, Tahara E: Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha. J Cancer Res Clin Oncol 119(7): 401-407, 1993
128. Liu P, Menon K, Alvarez E, Lu K, Teicher BA: Transforming growth factor-beta and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo. Int J Oncol 16(3): 599-610, 2000
129. Matsuzaki K, Date M, Furukawa F, Tahashi Y, Matsushita M, Sakitani K, Yamashiki N, Seki T, Saito H, Nishizawa M, Fujisawa J, Inoue K: Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma. Cancer Res 60(5): 1394-402, 2000
130. Genzyme press release: Genzyme General and Cambridge Antibody Technology Initiate Phase 1-2 Clinical Trial of CAT-192. November 12, 2001
131. Carrington L, Allamby D, McLeod D, Boulton M: RPE cell-mediated contraction of the retina; stimulation by TGF-β2 and reduction of stimulation in the presence of a human monoclonal antibody to human TGF-β2. Invest Ophtalmol Vis Sci 39: 566, 1998 (Abstract)
132. Ehrhart EJ, Segarini P, Tsang ML, Carroll AG, Barcellos-Hoff MH: Latent transforming growth factor beta1 activation in situ: quantitative and functional evidence after low-dose gamma-irradiation. FASEB J (12): 991-1002, 1997